Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 1,32 MB, PDF-dokument

  • Ahmed Ludvigsen AL-Mashhadi
  • Lasse Hjort Jakobsen
  • Anne Luise Thorsteinsson
  • Kaziwa Rasoul
  • Judith Melchior Haissman
  • Michael Buch Tøstesen
  • Mette Niemann Christoffersen
  • Jelena Jelicic
  • Jennifer Bøgh Jørgensen
  • Troels Thomsen
  • Andriette Dessau-Arp
  • Andreas P.H. Andersen
  • Mikael Frederiksen
  • Per Trøllund Pedersen
  • Michael Roost Clausen
  • Judit Meszaros Jørgensen
  • Tarec Christoffer El-Galaly
  • Thomas Stauffer Larsen
Outcome data of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) beyond the second line are scarce outside of clinical trials. Novel therapies in the R/R setting have been approved based on single-arm trials, but results need to be contextualized by real-world outcomes. Medical records from 3753 Danish adults diagnosed with DLBCL were reviewed. Patients previously treated with rituximab and anthracycline-based chemotherapy who received the third or later line (3 L+) of treatment after 1 January 2015, were included. Only 189 patients with a median age of 71 years were eligible. The median time since the last line of therapy was 6 months. Patients were treated with either best supportive care (22%), platinum-based salvage therapy (13%), low-intensity chemotherapy (22%), in clinical trial (14%) or various combination treatments (32%). The 2-year OS-/PFS estimates were 25% and 12% for all patients and 49% and 17% for those treated with platinum-based salvage therapy. Age ≥70, CNS involvement, elevated LDH and ECOG ≥2 predicted poor outcomes, and patients with 0–1 of these risk factors had a 2-year OS estimate of 65%. Only a very small fraction of DLBCL patients received third-line treatment and were eligible for inclusion. Outcomes were generally poor, but better in intensively treated, fit young patients with limited disease.
TidsskriftBritish Journal of Haematology
Udgave nummer3
Sider (fra-til)839-848
Antal sider10
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
The study was funded by Genentech, Inc. (USA).

Publisher Copyright:
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

ID: 387437491